ANNOUNCEMENT 06 Aug 2020

In August 2020, the European Investment Bank (EIB) signed a loan agreement with Evaxion Biotech to support the development of a platform for drug discovery exploiting Artificial Intelligence (AI) and the pipeline of potential vaccines and treatments targeting infectious diseases.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

EVAXION BIOTECH (IDFF) (a). EIB. Available at: https://www.eib.org/en/projects/loans/all/20190227

EVAXION BIOTECH (IDFF) (b). EIB. Available at: https://www.eib.org/en/projects/pipelines/all/20190227

Inception date: 06 Aug 2020 | Removal date: open ended

State loan

On 6 August 2020, the European Investment Bank (EIB) signed a loan agreement with Danish drug developer Evaxion Biotech to the value of EUR 20 million (approx. USD 23.7 million). The loan will support the development of a platform for drug discovery exploiting Artificial Intelligence (AI) and the pipeline of potential vaccines and treatments targeting infectious diseases.

A state act in the GTA database is assessed solely in terms of the extent to which its implementation affects foreign commercial interests. On this metric, the investment support granted here is discriminatory.

AFFECTED SECTORS

 

AFFECTED PRODUCTS